| Dr Faranak Bigdeli, DDS | |
|
18682 Beach Blvd Ste 100, Huntington Beach, CA 92648-2049 | |
| (714) 968-3522 | |
| (714) 968-3577 |
| Full Name | Dr Faranak Bigdeli |
|---|---|
| Gender | Female |
| Speciality | Dentist |
| Location | 18682 Beach Blvd Ste 100, Huntington Beach, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174718290 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | 49260 (California) | Primary |
| Entity Name | Bigdeli D.d.s. Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821478694 PECOS PAC ID: 8325301047 Enrollment ID: O20180411001570 |
News Archive
The cost of treating hepatitis C virus (HCV) could be cut up to 50 percent if mathematical models are used to predict when patients can safely stop taking direct-acting antiviral (DAA) medication, according to a new study by researchers at Loyola University Health System and Loyola University Chicago
The median profit margin of U.S. hospitals increased from near zero in the third quarter of 2008 to more than 8 percent in the second quarter of 2009, according to an analysis of hospital financial performance published today by Thomson Reuters.
Edward Calabrese, the University of Massachusetts Amherst environmental toxicologist who has been an outspoken critic of the current linear no-threshold (LNT) approach to risk assessment for radiation and toxic chemicals, now proposes a new approach integrating LNT with hormetic dose-response models.
During the Supreme Court's last hour of a marthon series of oral arguments, some justices indicated strong disagreement with the challenge brought by 26 states to the health law's Medicaid expansion.
Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Faranak Bigdeli, DDS 18682 Beach Blvd Ste 100, Huntington Beach, CA 92648-2049 Ph: (714) 968-3522 | Dr Faranak Bigdeli, DDS 18682 Beach Blvd Ste 100, Huntington Beach, CA 92648-2049 Ph: (714) 968-3522 |
News Archive
The cost of treating hepatitis C virus (HCV) could be cut up to 50 percent if mathematical models are used to predict when patients can safely stop taking direct-acting antiviral (DAA) medication, according to a new study by researchers at Loyola University Health System and Loyola University Chicago
The median profit margin of U.S. hospitals increased from near zero in the third quarter of 2008 to more than 8 percent in the second quarter of 2009, according to an analysis of hospital financial performance published today by Thomson Reuters.
Edward Calabrese, the University of Massachusetts Amherst environmental toxicologist who has been an outspoken critic of the current linear no-threshold (LNT) approach to risk assessment for radiation and toxic chemicals, now proposes a new approach integrating LNT with hormetic dose-response models.
During the Supreme Court's last hour of a marthon series of oral arguments, some justices indicated strong disagreement with the challenge brought by 26 states to the health law's Medicaid expansion.
Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.
› Verified 1 days ago
Dr. Janet Lillian Pezold, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 18700 Main St Ste 106, Huntington Beach, CA 92648 Phone: 714-847-9900 Fax: 714-847-7500 | |
Dr. Dale Edwin Brandon, DDS Dentist Medicare: Medicare Enrolled Practice Location: 18700 Main St, Suite 203, Huntington Beach, CA 92648 Phone: 714-375-7222 Fax: 714-375-9612 | |
Dr. Lisa Michelle Angelici, D.M.D., M.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 8101 Newman Ave, Suite D, Huntington Beach, CA 92647 Phone: 714-847-2650 Fax: 714-847-6614 | |
Dr. Nathan Linhvu Dinh, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 17742 Beach Blvd Ste 202, Huntington Beach, CA 92647 Phone: 714-602-3505 Fax: 714-602-3504 | |
Dr. Elizabeth Nguyen, DDS Dentist Medicare: Medicare Enrolled Practice Location: 19720 Beach Blvd, Ste. B, Huntington Beach, CA 92648 Phone: 714-593-1010 Fax: 714-593-2560 | |
Dr. Arthur Jan Jr., DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 17444 Beach Blvd, Huntington Beach, CA 92647 Phone: 714-842-6969 Fax: 714-842-5191 | |
Dr. Jeffrey Michael Coleman, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 6968 Warner Ave, Huntington Beach, CA 92647 Phone: 714-842-5593 |